Guardian Pharmacy Services (NYSE:GRDN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Guardian Pharmacy Services (NYSE:GRDN) announced its quarterly earnings data on Thursday. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.03, FiscalAI reports. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 31.45%. The business had revenue of $351.77 million for the quarter, compared to the consensus estimate of $340.45 million.

Here are the key takeaways from Guardian Pharmacy Services’ conference call:

• Guardian raised its 2026 outlook, now expecting revenue of $1.43 billion–$1.45 billion and adjusted EBITDA of $129 million–$131 million, up from prior ranges of $1.40 billion–$1.42 billion and $123 million–$127 million, respectively.
• Second-quarter adjusted EBITDA increased 19% to $29.7 million, supported by an 18% increase in gross profit, favorable product and payer mix, purchasing leverage, labor productivity, and operating efficiencies.
• The company reported continued operating expansion, including high-single-digit growth in residents served and script volumes, the acquisition of Wellness Concepts in Virginia, and the launch of a greenfield pharmacy in Lexington, Kentucky.
• Guardian said IRA-related pricing reductions will continue to pressure reported revenue, with second-half revenue expected to decline year over year by a low-single-digit percentage; management expects underlying revenue growth to remain in the high-single digits and believes the margin impact has been mitigated.
• Approximately 13.5 million Class B shares are expected to convert into Class A shares in late September, and 35 million–37 million employee, management, and director-held Class A shares could become eligible for sale after the next trading window following the third-quarter results, creating a potential supply overhang.

Guardian Pharmacy Services Trading Up 9.8%

NYSE:GRDN traded up $3.88 during mid-day trading on Friday, hitting $43.35. The company’s stock had a trading volume of 1,045,061 shares, compared to its average volume of 277,924. Guardian Pharmacy Services has a fifty-two week low of $19.30 and a fifty-two week high of $47.02. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of 42.09, a P/E/G ratio of 2.59 and a beta of 0.10. The stock has a fifty day moving average of $40.93 and a 200-day moving average of $37.09.

Institutional Investors Weigh In On Guardian Pharmacy Services

Several large investors have recently modified their holdings of the stock. Police & Firemen s Retirement System of New Jersey boosted its stake in Guardian Pharmacy Services by 20.4% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 6,070 shares of the company’s stock valued at $183,000 after buying an additional 1,028 shares in the last quarter. EntryPoint Capital LLC acquired a new position in Guardian Pharmacy Services during the fourth quarter worth $230,000. Intech Investment Management LLC bought a new position in shares of Guardian Pharmacy Services during the fourth quarter valued at $223,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Guardian Pharmacy Services in the 3rd quarter valued at $211,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Guardian Pharmacy Services by 31.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 7,899 shares of the company’s stock worth $207,000 after purchasing an additional 1,872 shares during the last quarter.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Weiss Ratings raised shares of Guardian Pharmacy Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday. Truist Financial boosted their price objective on shares of Guardian Pharmacy Services from $43.00 to $47.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Wall Street Zen lowered shares of Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Oppenheimer increased their target price on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Zacks Research downgraded Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.83.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.